No specific therapies exist for allergic rhinitis in the elderly. Treatments include pharmacological treatment, attempts at allergen-specific immunotherapy and a reduction or elimination of allergens from the patients’ environments. According to the guidelines, pharmacological treatment includes topical and oral drugs [
1,
3]. The type of drug used should be related to the clinical rhinitis symptoms [
1,
21]. Intranasal glucocorticosteroids and intranasal and/or oral antihistamine drugs are the first-line therapies [
1,
3]. The main problem with these therapies in the elderly is interactions between drugs or between drugs and diseases, especially in patients over 75 years of age. The risk of adverse events increases exponentially with the number of drugs used in older people [
36]. Additionally, this risk is higher in seniors with concomitant liver or renal impairment [
37]. Few studies have analyzed drug–drug interactions in general in elderly people, and most of the findings have suggested that drug metabolism is individual and not dependent on age. Accumulation of a drug that inhibits metabolism can also lead to the intensification of adverse events. One of the most important problems is interactions with anticholinergic drugs. Many drugs have antimuscarinic actions, and combining them in therapy can induce many serious adverse reactions, such as delirium episodes and urinary retention [
36]. Unfortunately, there are no detailed data about drugs used for allergic rhinitis.
5.1 Glucocorticosteroids
Glucocorticosteroids are used in upper airway diseases including allergic and non-allergic rhinitis, particularly non-allergic rhinitis with eosinophilia syndrome (NARES), acute and chronic rhinosinusitis with and without nasal polyps, and adenoid hypertrophy with or without middle ear disease [
37]. This evidence suggests that intranasal corticosteroids produce greater nasal symptom relief than topical antihistamines (H
1 receptor antagonists) even if no difference in ocular symptoms has been reported [
38,
39]. Corticosteroid nasal sprays include beclomethasone dipropionate, budesonide, ciclesonide, flunisolide, fluticasone furoate, fluticasone propionate, triamcinolone acetonide, and mometasone furoate. The design of topically active steroid formulations has provided a much better therapeutic ratio than oral corticosteroids. The pharmacodynamic and pharmacokinetic properties of these agents play important roles in facilitating local anti-inflammatory activity with a low rate of side effects [
40,
41]. No data suggest increased side effects after the use of these drugs in older patients [
36].
Many studies have confirmed that intranasal steroids are most beneficial in allergic rhinitis in general, due to their anti-inflammatory activities [
1,
41]. Steroids are also the recommended front-line treatment in every type of allergic rhinitis (intermittent or perennial) regardless of the severity in patients over 60 years of age [
3,
41]. However, few studies have investigated the prolonged use of nasal steroids in elderly people. These drugs are well tolerated by the elderly, with adverse reactions identical to those described in the younger population, such as epistaxis, dryness and a burning sensation in the nose [
11]. The prolonged use of these drugs frequently unblocks the nose and improves olfaction. No data are available regarding the role of chronically administered nasal steroids in osteoporosis and diabetes in elderly people; however, these patients should be monitored. Mometasone and ciclesonide have minimal bioavailability and therefore are the safest options; this effect is particularly important in the elderly [
33].
Oral glucocorticosteroids are not recommended for the treatment of allergic rhinitis in older patients [
21]. Some guidelines permit their use in some cases of severe allergic rhinitis; however, adverse events must be expected because these events are typical with systemic steroid use and may negate the benefits [
1]. Adverse events, including osteoporosis, diabetes, and arterial hypertension, after systemic steroid use are very individual but frequent and may not depend on age [
42]. Each patient must be individually analyzed for comorbidities.
5.2 Antihistamines
Antihistamines are a standard therapy for most types of allergic rhinitis, conjunctivitis and other allergic skin diseases in elderly patients [
21]. Most H
1 antihistamines have good absorption when administered orally, and the majority of H
1 antihistamines reach effective plasma concentration within 3 h after administration.
Based on our present knowledge, first-generation antihistamines are not recommended for the treatment of allergic rhinitis, especially in older patients, because there is a high risk of adverse reactions in elderly people due to the lack of receptor specificity as well as these drugs being able to cross the blood–brain barrier [
43]. Anxiety, confusion, dyskinesis, sedation or sleepiness are common in older patients, as are arrhythmias, urinary disturbances, constipation, hypotension, memory dysfunction, and problems with kinetic coordination that lead to falls [
44,
45]. Additionally, first-generation antihistamines frequently interact with other medications [
44].
Second-generation antihistamines are effective in elderly patients with allergic rhinitis in drops and oral forms. Their safety is based on a relatively low rate of passage across the blood–brain barrier. Simons observed that the new H
1-receptor antagonists cetirizine and loratadine were less likely to cause adverse central nervous system effects than the old H
1-antagonists in the elderly [
48]. However, no sufficient and precise data showing that these drugs are safe for the elderly are available.
Fexofenadine, cetirizine, loratadine, levocetirizine, desloratadine, bilastine and ebastine are most commonly used in elderly people [
21]. These drugs have a high affinity for the H
1 receptor and no or weak antagonist activity against the anticholinergic and alfa-adreno receptors [
36,
44]. The use of bilastine should be emphasized because it has been proven to have no effect on the cholinergic receptor, which is of great importance for safe application in elderly people [
45]. Unfortunately, desloratadine and loratadine have important interactions with the cholinergic receptors and thus are not indicated for patients with symptoms such as dry eye syndrome [
46,
47].
Some studies have established the anti-inflammatory effects of second-generation antihistamine drugs. Additionally, their interactions with other drugs are relatively slight [
48]. However, the majority of second-generation antihistamines are metabolized by the cytochrome 450 enzyme during their first pass through the liver and thus are not recommended for patients with significant liver dysfunction [
48]. Furthermore, for drugs with systemic absorption, impairment of renal or hepatic function may be important. For example, cetirizine is excreted by the kidney, and in patients with renal insufficiency it must be used with caution. No mention is made of this issue, and this is of particular importance because renal insufficiency is frequent in the elderly, even in those with normal serum creatinine. Therefore, patients with renal impairment should take lower daily doses of antihistamines such as azelastine, ebastine, desloratadine and cetirizine [
49,
50]. Apart from terfenadine, the remaining drugs in this group are cardiologically safe. However, parallel use of second-generation antihistamines (particularly ebastine) with drugs (i.e., ketoconazole, macrolides, quinolones, and cimetidine) that inhibit microsomal enzymes of the liver could stimulate arrhythmias in older patients [
51].
Topically applicable antihistamines, such as nasal sprays or eye drops, do not induce systemic adverse reactions or drug interactions [
50‐
52].
Doctors should choose antihistamines for elderly patients through careful consideration of the risk of adverse events based on laboratory renal and liver function tests. The reduction of the daily dose of oral antihistamine should be especially considered in patients over 75 years of age [
49,
51].
5.3 Decongestants
This group of topical or systemic drugs affects nasal blockage, which is a significant problem in affected patients. Therefore, these drugs are unfortunately over used and should not be a first-line therapy or used as a monotherapy, particularly for a prolonged period [
1,
21]. Notably, these drugs may generate many adverse events, such as increased arterial hypertension, headache, arousal, prostatism, and aggravation of glaucoma, and urination, which are particularly burdensome in the elderly [
21].
5.7 Allergen-Specific Immunotherapy
Allergen-specific subcutaneous immunotherapy is a safe and effective treatment method, particularly for allergic rhinitis in the general population. Several studies have confirmed this therapy’s efficacy in several randomized controlled immunotherapy trials, with a high degree of safety and efficacy. However, although doubts regarding the efficacy of immunotherapy in adults and children remain, no broad data exist for elderly patients. Despite the lack of objective contraindications, specific immunotherapy has not played a significant role in treating elderly patients, possibly because of the lack of evidence of safety in this group. This treatment should be considered only in patients with clinical nasal symptoms associated with a confirmation of an IgE-mediated reaction to a specific inhalant allergen. However, unstable circulatory, neoplasm and autoimmune diseases could be very important contraindications and should be very carefully checked in elderly patients [
54‐
56]. Furthermore, immunotherapy should be administered with caution to patients (especially in seniors) receiving beta-blockers or angiotensin-converting enzyme inhibitors because of the higher risk of anaphylactic shock [
56].
Recently, some evidence has indicated that allergen-specific immunotherapy is safe and effective in patients over 60 years of age [
57]. A double-blind, placebo-controlled trial with sublingual, allergen-specific immunotherapy to
Dermatophagoides pteronyssinus and
Dermatophagoides farinae in patients over 60 years of age confirmed its efficacy and safety during 3 years of therapy [
58]. A total of 51 subjects in the sublingual allergen-specific immunotherapy group and 57 in the placebo group were monitored for 3 years. The total nasal symptom score decreased by 44% in the active group and 6% in the placebo group at the end of the 3 years of therapy. The total medication score decreased significantly by a maximum of 51% in the active group and decreased significantly in the placebo control group. No adverse systemic reactions were reported during the study. These results were confirmed by a similar study with grass pollen [
59].
Despite sublingual immunotherapy, Asero assessed the efficacy of injection immunotherapy for birch and ragweed allergies in patients over 54 years of age [
60]. However, this trial was not placebo-controlled [
60]. In 2016, the first study with injections for allergen immunotherapy to grass pollen with a double-blind, placebo-controlled protocol was conducted. Sixty-two 60- to 75-year-old patients with seasonal allergic rhinitis and a confirmed grass pollen allergy according to a skin prick test, nasal provocation and measurement of serum IgE were included in the study. The patients were individually randomized to the active or placebo groups using a double-blind method. A total of 33 subjects in the subcutaneous immunotherapy (SCIT) group and 29 subjects in the placebo group were monitored for 3 years. The total nasal symptom score decreased by 76% in the active group and 5% in the placebo group after 3 years of SCIT. At the end of therapy, the total medication score of the active group decreased significantly by a maximum of 62%. No adverse systemic reactions were reported during therapy [
61].
More trials are necessary to determine the degree of effectiveness and safety of immunotherapy in elderly patients. A greater application of immunotherapy in elderly people may allow a reduction in chronic drug treatment, which can lead to polytherapy, typical in the elderly.
However, any prolonged therapy can lead to decreased adherence in elderly people. Moreover, some prolonged therapies may not be acceptable to elderly patients. The following factors influence the degree of adherence in elderly people: mental impairment, decreased vision, problems with swallowing and motor deficiencies [
62].
In these cases, doctors should monitor therapy, using recommended tools, such as questionnaires or assessment of the number of used drug packages [
62].